Formulations and methods for contemporaneous stabilization of active proteins during spray drying and storage

Patent metadata

Field	Value
Publication number	US-12064518-B2
Application number	US-202117508904-A
Country	US
Kind code	B2
Filing date	Oct 22, 2021
Priority date	Sep 19, 2014
Publication date	Aug 20, 2024
Grant date	Aug 20, 2024

Abstract

A method of treatment of plasma with a physiologically compatible spray dry stable acidic substance (SDSAS) prior to or contemporaneously with spray drying of the plasma that results in greater recovery and greater long-term stabilization of the dried plasma proteins as compared to spray dried plasma that has not be subject to the formulation method of the present invention, as well as compostions related to plasma dried by the methods of the present invention.

First claim

What is claimed is:

1. A method of producing a formulated plasma for spray drying, the method comprising:
a) combining one or more stable acidic substances with plasma, wherein the concentration of the stable acidic substance is in a range between about 0.001 mmol/ml and about 0.050 mmol/ml, wherein said one or more stable acidic substances is an acid or acidic salt that effectuates a pH, to thereby create a formulated plasma.

2. The method of claim 1 , wherein the method further comprises spray drying said formulated plasma in a plasma spray drying system to thereby obtain a spray dried formulated plasma.

3. The method of claim 1 , wherein said formulated plasma has a pH of about 5.5 to about 7.2.

4. The method of claim 1 , wherein the pH of the plasma is known prior to addition of said one or more stable acidic substances and the amount of said one or more stable acidic substances to be added plasma is determined based on the known pH of said plasma.

5. The method of claim 1 , wherein said one or more stable acidic substances is physiologically suitable for addition to plasma being spray dried or physiologically suitable for subjects into which reconstituted plasma is transfused.

6. The method of claim 1 , wherein the one or more stable acidic substances is selected from the group consisting of ascorbic acid, citric acid, gluconic acid, lactic acid, glycine hydrochloride, monosodium citrate, oxalic acid, halogenated acetic acids, arene sulfonic acids, molybdic acid, phosphotungstic acid, tungstic acid, chromic acid, sulfamic acid and any combination thereof.

7. The method of claim 1 , wherein citric acid is added to the plasma to increase citrate concentration by 7.4 mM.

8. A method of spray drying plasma, the method comprising:
a) combining one or more stable acidic substances and plasma, wherein the concentration of the stable acidic substance is in a range between about 0.001 mmol/ml and about 0.050 mmol/ml, wherein said one or more stable acidic substances is an acid or acidic salt that effectuates a pH, to thereby create a formulated plasma; and
b) spray drying said formulated plasma in a plasma spray drying system to thereby obtain spray dried formulated plasma.

9. The method of claim 8 , wherein the when the spray dried formulated plasma is stable at ambient temperature for at least 7 days.

10. The method of claim 8 , wherein spray dried formulated plasma is stored for at least two weeks.

11. The method of claim 8 , wherein the spray dried formulated plasma is stored under refrigeration, at ambient temperature or at a higher temperature.

12. The method of claim 8 , wherein the spray dried formulated plasma has a moisture content of between about 2%-10%.

13. The method of claim 8 , wherein when combining the plasma with the one or more stable acidic substances occurs up to 30 minutes before spray drying.

14. The method of claim 8 , wherein when combining the plasma with the one or more stable acidic substances occurs immediately prior to or contemporaneously with spray drying.

15. A method of producing plasma suitable for transfusion into a recipient, the method comprising:
a) combining one or more stable acidic substances and plasma, wherein the concentration of the stable acidic substance is in a range between about 0.001 mmol/ml and about 0.050 mmol/ml, wherein said one or more stable acidic substances is an acid or acidic salt that effectuates a pH, to thereby create a formulated plasma;
b) spray drying said formulated plasma in a plasma spray drying system to thereby obtain spray dried formulated plasma; and
c) reconstituting the spray dried formulated plasma to thereby obtain reconstituted plasma suitable for transfusion into a recipient.

16. The method of claim 15 , wherein the reconstituted plasma has a pH of about 6.8 to about 7.6.

17. The method of claim 16 , wherein when the reconstituted plasma has a physiological pH.

18. The method of claim 15 , wherein said plasma comprises CPD (citrate phosphate dextrose solution) plasma or is WB (whole blood) plasma.

19. The method of claim 15 , wherein the reconstitution solution comprises a substance selected from the group consisting of: sterile water, sodium bicarbonate, disodium phosphate, and glycine sodium hydroxide.

20. The method of claim 15 , wherein von Willebrand factor activity from reconstituted plasm a is between about 5 and about 40 percentage points greater than the von Willebrand factor activity obtained from reconstituted plasm a that has been not undergone formulation with one or more stable acidic substances.

21. The method of claim 20 , wherein von Willebrand factor activity from reconstituted plasma is between about 10 and about 35 percentage points greater than the von Willebrand factor activity obtained from reconstituted plasm a that has been not undergone formulation with one or more stable acidic substances.

22. The method of claim 15 , further comprising measuring activity of Factors V, VII, VIII and IX or any combination thereof to determine stability of the reconstituted plasma.

23. A method of producing plasma suitable for transfusion into a recipient, the method comprising:
a) combining one or more stable acidic substances and plasma, wherein the concentration of the stable acidic substance is in a range between about 0.001 mmol/ml and about 0.050 mmol/ml, wherein said one or more stable acidic substances is an acid or acidic salt that effectuates a pH, to thereby create a formulated plasma;
b) spray drying said formulated plasma in a plasma spray drying system to thereby obtain spray dried formulated plasma;
c) storing the spray dried formulated plasma; and
d) reconstituting the spray dried formulated plasma to thereby obtain reconstituted plasma suitable for transfusion into a recipient.

24. The method of claim 23 , wherein spray dried formulated plasma is stored for at least two weeks.

25. The method of claim 23 , wherein the spray dried formulated plasma is stored under refrigeration, at ambient temperature or at a higher temperature.

26. A method of producing spray dried formulated plasma, the method comprising providing:
a) plasma,
b) one or more physiologically compatible stable acidic substances, wherein said one or more stable acidic substances is an acid or acidic salt that effectuates a pH and is physiologically suitable for addition to plasma being spray dried or physiologically suitable for subjects into which reconstituted plasma is transfused, wherein the concentration of the stable acidic substance is in a range between about 0.001 and about 0.050 mmol/ml, and wherein when plasma and one or more stable acidic substances are combined, the combination creates a formulated plasma, and
c) a plasma spray drying system for spray drying the formulated plasma to thereby create a spray dried formulated plasma.

27. The method of claim 26 , wherein said formulated plasma has a pH of about 5.5 to about 7.2.

28. The method of claim 26 , wherein the pH of the plasma is known prior to addition of said one or more stable acidic substances and the amount of said one or more stable acidic substances to be added plasma is determined based on the known pH of said plasma.

29. The method of claim 26 , wherein the one or more stable acidic substances is selected from the group consisting of ascorbic acid, citric acid, gluconic acid, lactic acid, gly

Assignees

• Velico Medical Inc

Inventors

• Liu Qiyong Peter
• Cui Junqing
• Lucien Rud Karly
• Carney Ryan
• Sohn Jihae
• Arya Michelle
• Khan Abdul W

Classifications

• F26B3/04

  the gas or vapour circulating over or surrounding the materials or objects to be dried (F26B3/14 takes precedence) · CPC title

• B01J2219/00177

  controlling the pH · CPC title

• B01J19/06

  Solidifying liquids (making microcapsules B01J13/02) · CPC title

• A61K35/16

  Blood plasma; Blood serum (umbilical cord blood A61K35/51) · CPC title

• A61K9/1617

  Organic compounds, e.g. phospholipids, fats · CPC title